Remicade (infliximab)

22:45 EST 23rd November 2017 | BioPortfolio

Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; Crohn's Disease in children 6 years and older, and adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children 6 years and older and adults that have not responded well to other medicines

2012 sales: $8.215 billion [$6.139 billion J&J + $2.076 billion Merck & Co.]

Drug maker: Johnson & Johnson and Merck & Co.

Quick Search

review and buy Remicade (infliximab) market research data and corporate reports here